--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-25-071904" form_type: "8-K" ticker: null cik: "0001444380" company_name: "NEVRO CORP" filed_at: "2025-04-03T23:59:59+00:00" generated_at: "2026-05-23T22:25:27.152165+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 1.0 calibrated_materiality_score: 1.0 confidence: "high" source: SEC EDGAR --- # Completed acquisition by Globus Medical for $5.85/share; Nevro now wholly owned subsidiary ## Summary - Holders of Nevro shares received $5.85 per share in cash; stock options and RSUs cancelled for cash. - On April 1, Nevro repaid ~$190M principal plus ~$2.61M accrued interest on 2.75% Convertible Senior Notes. - Nevro terminated its $200M Credit Agreement, paying ~$227.1M including principal, interest, and fees. - All Nevro directors resigned; Globus designees installed. Nevro requested delisting from NYSE and plans to deregister. ## SEC filing metadata - accession: 0001193125-25-071904 - form_type: 8-K - cik: 0001444380 - company_name: NEVRO CORP - filed_at: 2025-04-03T23:59:59+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 1.0 - calibrated_materiality_score: 1.0 - confidence: high - sec_items: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/d912761d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-25-071904 - JSON: https://secwatch.observer/filing/0001193125-25-071904.json - Plain text: https://secwatch.observer/filing/0001193125-25-071904.txt ## Key facts - Executive change Kevin O’Boyle resigned as Director at NEVRO CORP. - Action: resigned - Role: Director source text: each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm - Executive change Karen N. Prange resigned as Director at NEVRO CORP. - Action: resigned - Role: Director source text: each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm - Executive change Sri Kosaraju resigned as Director at NEVRO CORP. - Action: resigned - Role: Director source text: each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm - Executive change Kevin Thornal resigned as Director at NEVRO CORP. - Action: resigned - Role: Director source text: each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm - Executive change Shawn T. McCormick resigned as Director at NEVRO CORP. - Action: resigned - Role: Director source text: each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm - Executive change Michael DeMane resigned as Director at NEVRO CORP. - Action: resigned - Role: Director source text: each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm - Executive change Kirt Karros resigned as Director at NEVRO CORP. - Action: resigned - Role: Director source text: each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm - Executive change D. Keith Grossman resigned as Director at NEVRO CORP. - Action: resigned - Role: Director source text: each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm - Executive change Susan Siegel resigned as Director at NEVRO CORP. - Action: resigned - Role: Director source text: each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm - Executive change Elizabeth Weatherman resigned as Director at NEVRO CORP. - Action: resigned - Role: Director source text: each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm - Executive change Keith Pfeil was appointed as Director at NEVRO CORP. - Action: appointed - Role: Director source text: each of Daniel Scavilla and Keith Pfeil, the directors of Merger Sub immediately prior to the Effective Time, became the directors of Nevro. evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm - Executive change Daniel Scavilla was appointed as Director at NEVRO CORP. - Action: appointed - Role: Director source text: each of Daniel Scavilla and Keith Pfeil, the directors of Merger Sub immediately prior to the Effective Time, became the directors of Nevro. evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm - Governance Changes NEVRO CORP: Certificate of incorporation amended and restated in its entirety as of the Effective Time pursuant to Merger Agreement. - Change: charter amendment source text: the certificate of incorporation of Nevro and the bylaws of Nevro, each as in effect immediately prior to the Effective Time, were each amended and restated in their entirety evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm - Governance Changes NEVRO CORP: Bylaws amended and restated in their entirety as of the Effective Time pursuant to Merger Agreement. - Change: bylaw amendment source text: the certificate of incorporation of Nevro and the bylaws of Nevro, each as in effect immediately prior to the Effective Time, were each amended and restated in their entirety evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm - M&A Transactions NEVRO CORP underwent a change of control involving Globus Medical, Inc. for $5.85 per Nevro Share in cash (closed 2025-04-03). - Action: change of control - Counterparty: Globus Medical, Inc. - Consideration: $5.85 per Nevro Share in cash - Closing: 2025-04-03 source text: or Nevro or by any direct or indirect wholly owned subsidiary of Globus, Merger Sub or Nevro was canceled and extinguished and automatically converted into the right to receive $5.85 per Nevro Share in cash (the “Merger Consideration”), without interest and subject to any applicable withholding taxes. In addition, effective as of immediately prior to the evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000119312525071904/0001193125-25-071904-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.